vadimezan has been researched along with gardiquimod in 2 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (gardiquimod) | Trials (gardiquimod) | Recent Studies (post-2010) (gardiquimod) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 38 | 0 | 30 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Cho, MY; Choi, I; Hong, KS; Korm, S; Lee, H; Lee, JY; Lim, YT; Park, C; Seth, A | 1 |
2 other study(ies) available for vadimezan and gardiquimod
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.
Topics: Aminoquinolines; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Dendritic Cells; Drug Delivery Systems; Imidazoles; Immunotherapy; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Nanoparticles; Toll-Like Receptor 7; Toll-Like Receptor 8; Xanthones | 2017 |